We just covered the 14 Best Defensive Stocks to Invest In Now and Gilead Sciences, Inc. (NASDAQ:GILD) ranks 4th on this list.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stem cell therapy stocks to buy. Gilead Sciences, Inc. (NASDAQ:GILD) ...

Gilead (GILD) wraps up $7.8B Arcellx deal, gaining anito-cel therapy. Stock tests key support at $128 with oversold RSI ...

Gilead Sciences ( GILD) shares snapped a six-session losing streak, closing 0.56% higher at $133.64 on Thursday. The biopharmaceutical company began its downward trend on April 15, and the stock lost ...

HIV franchise still drives growth, oncology M&A faces skepticism, & valuation looks cheap at ~16x P/E. Click for this GILD ...

In the latest trading session, Gilead Sciences (GILD) closed at $130.40, marking a -2.42% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day.

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Check out the latest Gilead Sciences Inc. (GILD) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.

Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus ...